681853-96-3

Upstream product

• 95666-80-1 (1R)-(-)-1-[(4R,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-2-(triphenylmethyloxy)ethan-1-ol 
• 532-20-7 D-Ribose 
• 67814-68-0 2,3-O-isopropylidene-D-ribofuranose 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 54503-64-9 2,3-O-isopropylidene-5-O-trityl-D-ribofuranose 

Downstream Products

• 865838-12-6 (1R)-(-)-1-[(4S,5S)-2,2-dimethyl-5-vinyl-1,3-dioxolan-4-yl]-1-(triphenylmethyloxymethyl)-2-propen-1-ol 
• 1026381-17-8 C₂₉H₃₁NO₄ 
• 902799-71-7 C₃₀H₃₂O₄ 
• 805245-40-3 tert-butyl(((3aR,4R,6aR)-5-iodo-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)diphenylsilane 
• 805245-41-4 tert-butyl(((3aR,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)diphenylsilane 
• 805245-39-0 (3aS,4R,6aR)-5-iodo-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 805245-42-5 (3aS,4R,6aR)-5-fluoro-2,2-dimethyl-6-((trityloxy)methyl)-4,6a-dihydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 805245-38-9 (3aR,6aR)-5-iodo-2,2-dimethyl-6-((trityloxy)methyl)-3aH-cyclopenta[d][1,3]dioxol-4(6aH)-one 
• 865838-14-8 (3R,4S,6aR)-3-benzoyl-1-(5-fluoro-2,2-dimethyl-6-trityloxymethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-yl)-1H-pyrimidine-2,4-dione 
• 864181-54-4 (3aS,4R,6R,6aR)-2,2-dimethyl-6-(methylamino)-6-[(trityloxy)methyl]-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 
• 864181-53-3 (1R,2R,6R,7R)-4,4,9-trimethyl-1-[(trityloxy)methyl]-3,5,8-trioxa-9-aza-tricyclo[5.2.1.0^2,6]decane 
• 865838-13-7 (3aS,4R,6aS)-2,2-dimethyl-4-trityloxymethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-ol 
• 88559-56-2 (3aR,6aR)-2,2-dimethyl-6-[(trityloxy)methyl]-3a,6a-dihydro-4H-cyclopenta[d][1,3]dioxol-4-one 

Relevant academic research and scientific papers

Tumor immunity compound and application thereof

Disclosed are a tumor immunity compound and an application thereof. The invention discloses a compound as shown in the formula (I), optical isomers thereof, and pharmaceutically acceptable salts thereof, and an application of the compound as an STING agonist.

Stereoselective synthesis of 3-hydroxymethyl-D-cyclopentenone, the versatile intermediate for the synthesis of carbocyclic nucleosides

The preparative and stereoselective synthesis (45-50% overall yields, >50 g scale) of the key carbasugars 7a-d was achieved from D-ribose via stereoselective Grignard reaction and oxidative rearrangement as key reactions. Copyright Taylor & Francis, Inc.

An improved approach to chiral cyclopentenone building blocks. Total synthesis of pentenomycin I and neplanocin A

An improved approach to enantiomerically pure hydroxylated cyclopentenones is reported here, which involves intramolecular nitrone cycloaddition of sugar-derived chiral pent-4-enals and hex-5-en-ones-2 followed by N-O bond cleavage, quaternization of the amine thus produced, and finally oxidative elimination of the amino group. Synthesis of pentenomycin I and neplanocin A is described following this methodology.

Nucleoside derivatives and therapeutic uses therof

The present invention relates to nucleoside derivatives represented by general formulas I and II, their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperprolifera

Preparative and Stereoselective Synthesis of the Versatile Intermediate for Carbocyclic Nucleosides: Effects of the Bulky Protecting Groups to Enforce Facial Selectivity

The preparative and stereoselective synthesis (45-50% overall yields) of the target compound 17 has been accomplished from D-ribose. The bulky protecting groups such as TBDPS and Trityl enforced the facial selectivity during Grignard reaction to give the